Advertisement
Canada markets closed

  • S&P/TSX

    22,269.12
    +197.41 (+0.89%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • DOW

    38,686.32
    +574.84 (+1.51%)
     

  • CAD/USD

    0.7339
    +0.0028 (+0.38%)
     

  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     

  • Bitcoin CAD

    92,119.88
    -1,095.77 (-1.18%)
     

  • CMC Crypto 200

    1,434.66
    +6.09 (+0.43%)
     

  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     

  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     

  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     

  • NASDAQ

    16,735.02
    -2.06 (-0.01%)
     

  • VOLATILITY

    12.92
    -1.55 (-10.71%)
     

  • FTSE

    8,275.38
    +44.33 (+0.54%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

  • CAD/EUR

    0.6762
    +0.0016 (+0.24%)
     

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

PR Newswire
·2 min read

BOSTON, May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.

A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.

ADVERTISEMENT

Elevation Oncology Investor and Media Contact

Hannah Deresiewicz, 212-362-1200
EVP, Managing Director, Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

(PRNewsfoto/Elevation Oncology)
(PRNewsfoto/Elevation Oncology)

 

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-citizens-jmp-life-sciences-conference-302137883.html

SOURCE Elevation Oncology